The Latest Analyst Ratings For Axsome Therapeutics
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has received diverse analyst ratings over the last three months, with a notable increase in the average 12-month price target to $131.38 from $90.00, indicating a 45.98% rise. The company, a clinical-stage biopharmaceutical firm focusing on CNS disorders, has shown a significant revenue growth rate of 243.07% as of September 30, 2023. However, it faces challenges with a net margin of -107.62% and below-average ROE and ROA. Analysts from firms like UBS, RBC Capital, Cantor Fitzgerald, Piper Sandler, HC Wainwright & Co., and Citigroup have provided ratings ranging from Buy to Overweight, with price targets up to $180.00.
February 06, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics has received positive analyst ratings and a significant increase in its average 12-month price target, reflecting strong growth prospects. Despite financial challenges, the company's substantial revenue growth and pipeline products for CNS disorders position it favorably.
The increase in the average 12-month price target for AXSM, along with positive analyst ratings, suggests optimism about the company's future performance. The substantial revenue growth rate further supports this view, although challenges in profitability and efficiency metrics are noted. The diverse analyst perspectives and the significant upward revision in price targets indicate strong investor interest and potential for short-term price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100